-

Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence

Integrated technology provides a true system approach to gas chromatography

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced the Agilent 8697 Headspace Sampler, the first headspace sampler with integrated gas chromatography communication. It marks the expansion of intelligence capability that was first launched with the Agilent Intuvo 9000 GC System in 2016 and later in 2019 with the Agilent 8890 and 8860 GC Systems.

“We recognized the increasing needs of our customers, especially in the pharma space, to have greater remote access and increased instrument intelligence,” said Mike Zhang, vice president and general manager of Agilent’s Gas Phase Separations Division. “With the introduction of Intuvo four years ago and the 8890 and 8860 GCs two years ago, Agilent has been expanding the intelligence, diagnostics, and troubleshooting capabilities of our GC platforms.”

The 8697 offers several benefits. Advanced hardware features, such as a microchannel-based EPC (electronic pneumatic control) module with atmospheric pressure compensation and valve-based sampling, allow for unprecedented precision and performance. Customers will also have increased troubleshooting capabilities, more robust connections between the HS and GC system, and integrated instrument connectivity through the increased headspace-gas chromatography system intelligence.

On a more detailed level, removable sample racks can be exchanged while the headspace sampler is operating so that customers can add samples while the sequence is running. An isolated carrier flow path allows for alternate carrier gas use and safely vents vials. Also, because the complete HS-GC system is on the GC touch screen, customers can easily communicate with it anywhere the lab network will allow.

“The 8697 fits into the ‘sweet spot’ for a number of samples customers tell us they want,” added Eric Denoyer, associate vice president of marketing for Agilent’s Gas Phase Separations Division. “We’re excited to continue introducing smart, connected instruments and extend beyond the GC platform.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom